Research Project 1- Targeted Nanocarrier Combination Based Therapy for Lung Cancer - Dr. Mandip Sachdeva: Lung cancer incidence rate in African American is 50% higher than that of white Americans. African Americans have the highest cancer incidence and mortality rates of any racial/ethnic minority group in the U.S. Furthermore, its incidence continues to steadily rise among both African and white American women. The age adjusted death rate among African American population from lung cancer was found to be 12%. The recommended first line of chemotherapy In NSCLC is platinum based combination chemotherapy. Despite recent advances in chemotherapy, response rates in NSCLC remain <50% and also chemotherapy is associated with adverse effects. This necessitates investigation on chemotherapeutic options having potent anticancer activity and lower side effects to improve therapeutic outcomes in treatment of lung cancer. Noscapine (Nos). an antimicrotubular agent, has been shown to have promising anticancer activity. Our laboratory has already demonstrated that oral administration of Nos significantiy regress tumor growth in dose dependent manner in H460 xenograft tumor model. The use of Nos has been limited due to extensive first pass metabolism and poor bioavailability. Therefore, enhancing oral bioavailability of Nos using nanocarrier delivery system which can bypass the first pass effect (coated with mannosamine) and delivering in combination with chemotherapeutic agents to exert synergistic antitumor activity is a novel approach in treatment of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Exploratory Grants (P20)
Project #
5P20MD006738-03
Application #
8611736
Study Section
Special Emphasis Panel (ZMD1-RN)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
3
Fiscal Year
2014
Total Cost
$145,024
Indirect Cost
$38,281
Name
Florida Agricultural and Mechanical University
Department
Type
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Boakye, Cedar H A; Patel, Ketan; Doddapaneni, Ravi et al. (2016) Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids Surf B Biointerfaces 143:156-67
Tawk, Rima; Dutton, Matthew (2016) Racial Differences in Length of Stay for Patients Who Leave Against Medical Advice from U.S. General Hospitals. Int J Environ Res Public Health 13:
Ramsubhag, Ron R; Massaro, Chelsea L; Dadich, Christina M et al. (2016) Synthesis of ""neoprofen"", a rigidified analogue of ibuprofen, exemplifying synthetic methodology for altering the 3-D topology of pharmaceutical substances. Org Biomol Chem 14:7855-8
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Hedrick, Erik; Lee, Syng-Ook; Doddapaneni, Ravi et al. (2016) NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration. Mol Cell Biol 36:1383-94
Gangapuram, Madhavi; Jean, Riccardo; Mazzio, Elizabeth et al. (2016) Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells. Anticancer Res 36:5043-5052
Zarmouh, Najla O; Messeha, Samia S; Elshami, Faisel M et al. (2016) Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors. European J Med Plants 15:
Patel, Ketan; Doddapaneni, Ravi; Chowdhury, Nusrat et al. (2016) Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine (Lond) 11:1377-92
Andey, Terrick; Patel, Apurva; Marepally, Srujan et al. (2016) Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS One 11:e0146804
Mochona, Bereket; Qi, Xin; Euynni, Suresh et al. (2016) Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem Lett 26:2847-51

Showing the most recent 10 out of 81 publications